Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls.

Kim J, Luo W, Wang M, Wegman-Ostrosky T, Frone MN, Johnston JJ, Nickerson ML, Rotunno M, Li SA, Achatz MI, Brodie SA, Dean M, de Andrade KC, Fortes FP, Gianferante M, Khincha P, McMaster ML, McReynolds LJ, Pemov A, Pinheiro M, Santiago KM, Alter BP, Caporaso NE, Gadalla SM, Goldin LR, Greene MH, Loud J, Yang XR, Freedman ND, Gapstur SM, Gaudet MM, Calista D, Ghiorzo P, Fargnoli MC, Nagore E, Peris K, Puig S, Landi MT, Hicks B, Zhu B, Liu J, Sampson JN, Chanock SJ, Mirabello LJ, Morton LM, Biesecker LG, Tucker MA, Savage SA, Goldstein AM, Stewart DR.

Genome Med. 2018 Dec 24;10(1):99. doi: 10.1186/s13073-018-0607-5.

2.

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.

Shi J, Hua X, Zhu B, Ravichandran S, Wang M, Nguyen C, Brodie SA, Palleschi A, Alloisio M, Pariscenti G, Jones K, Zhou W, Bouk AJ, Boland J, Hicks B, Risch A, Bennett H, Luke BT, Song L, Duan J, Liu P, Kohno T, Chen Q, Meerzaman D, Marconett C, Laird-Offringa I, Mills I, Caporaso NE, Gail MH, Pesatori AC, Consonni D, Bertazzi PA, Chanock SJ, Landi MT.

PLoS Med. 2016 Dec 6;13(12):e1002162. doi: 10.1371/journal.pmed.1002162. eCollection 2016 Dec.

3.

TET2 binds the androgen receptor and loss is associated with prostate cancer.

Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, Bouk AJ, Butcher D, Wang Z, Sun L, Misner K, Tan W, Esnakula A, Esposito D, Huang WY, Hoover RN, Tucker MA, Keller JR, Boland J, Brown K, Anderson SK, Moore LE, Isaacs WB, Chanock SJ, Yeager M, Dean M, Andresson T.

Oncogene. 2017 Apr;36(15):2172-2183. doi: 10.1038/onc.2016.376. Epub 2016 Nov 7.

4.

Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.

Brodie SA, Li G, Harvey D, Khuri FR, Vertino PM, Brandes JC.

Oncotarget. 2015 Oct 13;6(31):30773-86. doi: 10.18632/oncotarget.5040.

5.

Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.

Brodie SA, Li G, Brandes JC.

Respir Med. 2015 Jan;109(1):131-6. doi: 10.1016/j.rmed.2014.11.004. Epub 2014 Nov 21.

6.

Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.

Brodie SA, Lombardo C, Li G, Kowalski J, Gandhi K, You S, Khuri FR, Marcus A, Vertino PM, Brandes JC.

PLoS One. 2014 Sep 15;9(9):e107124. doi: 10.1371/journal.pone.0107124. eCollection 2014.

7.

Could valproic acid be an effective anticancer agent? The evidence so far.

Brodie SA, Brandes JC.

Expert Rev Anticancer Ther. 2014 Oct;14(10):1097-100. doi: 10.1586/14737140.2014.940329. Epub 2014 Jul 14.

8.

Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.

Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR, Brandes JC.

Cancer. 2014 May 1;120(9):1394-400. doi: 10.1002/cncr.28479. Epub 2014 Mar 24.

9.

Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.

Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR, Vertino PM, Brandes JC.

Cancer Prev Res (Phila). 2014 Mar;7(3):351-61. doi: 10.1158/1940-6207.CAPR-13-0254. Epub 2014 Jan 17.

10.

Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells.

Kim CW, Song H, Kumar S, Nam D, Kwon HS, Chang KH, Son DJ, Kang DW, Brodie SA, Weiss D, Vega JD, Alberts-Grill N, Griendling K, Taylor WR, Jo H.

Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1350-9. doi: 10.1161/ATVBAHA.112.300287. Epub 2013 Apr 4.

11.

CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.

Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, Brock MV, Ribeiro MJ, Ramalingam SS, Owonikoko TK, Khuri FR, Brandes JC.

Clin Cancer Res. 2013 Mar 15;19(6):1603-11. doi: 10.1158/1078-0432.CCR-12-2995. Epub 2013 Feb 5.

12.

Targeted therapy of non-small-cell lung carcinoma.

Tiwari D, Brodie SA, Brandes JC.

Ther Adv Respir Dis. 2012 Feb;6(1):41-56. doi: 10.1177/1753465811404590. Epub 2011 Jul 5. Review.

PMID:
21730004
13.

Amino acid substitutions in yeast TFIIF confer upstream shifts in transcription initiation and altered interaction with RNA polymerase II.

Ghazy MA, Brodie SA, Ammerman ML, Ziegler LM, Ponticelli AS.

Mol Cell Biol. 2004 Dec;24(24):10975-85.

14.

The effects of superoxide dismutase in gerbils with bacterial meningitis.

Ge NN, Brodie SA, Tinling SP, Brodie HA.

Otolaryngol Head Neck Surg. 2004 Nov;131(5):563-72.

PMID:
15523427

Supplemental Content

Loading ...
Support Center